impact factor, citescore
logo
 

Full Papers

 

Clinical course of COVID-19 infections in patients with Behçet’s disease in The Netherlands


1, 2, 3, 4

 

  1. Department of Internal Medicine, Division of Allergy and Clinical Immunology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  2. Department of Internal Medicine, Division of Allergy and Clinical Immunology, and Department of Immunology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  3. Department of Internal Medicine, Division of Allergy and Clinical Immunology, and Department of Immunology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
  4. Department of Internal Medicine, Division of Allergy and Clinical Immunology, and Department of Immunology, Erasmus University Medical Centre, Rotterdam, The Netherlands. j.vanlaar@erasmusmc.nl

CER15292
2022 Vol.40, N°8
PI 1504, PF 1509
Full Papers

Free to view
(click on article PDF icon to read the article)

PMID: 35819802 [PubMed]

Received: 01/11/2021
Accepted : 21/02/2022
In Press: 01/07/2022
Published: 14/09/2022

Abstract

OBJECTIVES:
The aim of this study is to investigate the cumulative incidence and the severity of COVID-19 infections in patients with Behçet’s disease.
METHODS:
A retrospective cohort study of patients with Behçet’s disease was conducted. We obtained the data systematically from electronic patient files and through telephone interviews between February 2020 and May 1, 2021. Main outcomes were COVID-19 infection, disease duration, hospitalisation, intensive care admission and mortality. Secondary outcome was adherence to quarantine measures as recommended by the government.
RESULTS:
185 Behçet’s disease patients were included (mean age 42.2 years, 54% female); 58% of the patients were receiving colchicine, 30% anti-TNFα, 16% azathioprine and 8% systemic steroids. 30 patients (16.2%) were positive for COVID-19. Within our cohort, the cumulative incidence of COVID-19 was therefore 16.2% (95% CI 11.2-22.3%), which is significantly increased when compared to the general Dutch population (8.7% (95% CI 8.72-8.73%)) (p < 0.001). Four out of 30 (13%) patients were admitted to the hospital. There was no COVID-19 related mortality observed. Patients adhered to government measures; except in the period between the 1st of June and the 28th of September, this cohort received more visitors than in period 1 and 3.
CONCLUSIONS:
In this cohort, Behçet’s disease patients have a higher risk for COVID-19 infection, without an increase of virus-related mortality. The course of COVID-19 disease in this cohort is relatively mild, with a lower admission rate than expected of patients using immunosuppressive medication.

DOI: https://doi.org/10.55563/clinexprheumatol/xdx09v

Rheumatology Article

Rheumatology Addendum